Search News Archives
Special Offers and Promotions
Conferences | Events
BioTek Expands Next Generation Hybrid Microplate Reader Instrumentation
BioTek, the market leader in Hybrid Microplate Detection Technology, has released its newest product, the SynergyTM H1 Hybrid Multi-Mode Microplate Reader. This latest addition to its "patent-pending" product line expands the performance, versatility and flexibility offered by Hybrid Technology.
Synergy H1 is offered as highly flexible, high value monochromator-based Multi-Mode microplate reader for UV-Vis absorbance, top and bottom fluorescence, and luminescence assays that can be easily upgraded to a "hybrid" reader with the addition of a high performance filter module. This independent filter module with dichroic mirrors supports Fluorescence Polarization (FP), Time-Resolved Fluorescence (TRF), TR-FRET and BRET assays with ultra-high sensitivity.
Synergy H1 includes BioTek's well recognized Gen5TM Data Analysis Software for advanced reader control, data analysis, graphing, exporting and reporting. Additionally, Synergy H1 is compatible with BioTek's Take3TM Multi-Volume Plate that measures up to sixteen 2 µL samples, two BioCells or a standard cuvette for fast and simple multi-volume, multi-sample analysis.
"Synergy H1 provides robust performance and for the first time makes "Hybrid Technology" available to life science, academic and small biotechnology companies at a very competitive price," notes Gary Barush, BioTek's Director of Marketing and Sales. "The modular architecture means that customers can easily upgrade from a monochromator-based multi-mode reader to a hybrid reader offering true versatility and unlimited assay use."
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
For further information please visit www.biotek.com